Telix Pharmaceuticals (OTCMKTS:TLPPF) Stock Price Up 6.3% – Here’s Why

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) rose 6.3% during trading on Monday. The stock traded as high as $12.40 and last traded at $12.40. Approximately 400 shares traded hands during trading, a decline of 90% from the average daily volume of 4,129 shares. The stock had previously closed at $11.67.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $20.00.

Telix Pharmaceuticals Trading Down 9.2%

The stock has a 50 day moving average of $11.20 and a 200-day moving average of $10.38.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for cancer imaging and treatment. Its platform combines radioactive isotopes with targeting molecules designed to identify or bind to specific biological markers associated with disease.

The company’s principal commercial product is Illuccix, a gallium-68 PSMA-PET imaging agent used to help detect and manage prostate cancer. Telix is also developing a pipeline of diagnostic and therapeutic radiopharmaceuticals targeting cancers including kidney, brain, and prostate tumors, as well as other medical conditions.

Founded in 2015 and headquartered in Melbourne, Australia, Telix serves healthcare markets across Australia, the United States, Europe, and other international regions through regulatory approvals, commercial partnerships, and distribution arrangements.